Harrow Begin Period Cash Flow vs Capital Expenditures Analysis
HROWL Stock | USD 25.39 0.00 0.00% |
Harrow Health financial indicator trend analysis is much more than just examining Harrow Health 8625 latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Harrow Health 8625 is a good investment. Please check the relationship between Harrow Health Begin Period Cash Flow and its Capital Expenditures accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.
Begin Period Cash Flow vs Capital Expenditures
Begin Period Cash Flow vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Harrow Health 8625 Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Harrow Health's Begin Period Cash Flow and Capital Expenditures is 0.95. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Harrow Health 8625, assuming nothing else is changed. The correlation between historical values of Harrow Health's Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Harrow Health 8625 are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., Harrow Health's Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.95 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Harrow Health 8625 to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Harrow Health operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Harrow Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harrow Health 8625 current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.At this time, Harrow Health's Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to rise to 4,830 this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.73.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 72.5M | 88.6M | 130.2M | 136.7M | Depreciation And Amortization | 2.4M | 3.7M | 12.3M | 13.0M |
Harrow Health fundamental ratios Correlations
Click cells to compare fundamentals
Harrow Health Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harrow Health fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 59.1M | 57.5M | 98.3M | 157.0M | 312.2M | 327.8M | |
Other Current Liab | 2.4M | 1.7M | 4.9M | (836K) | 27.0M | 28.4M | |
Total Current Liabilities | 12.3M | 10.8M | 9.7M | 18.6M | 49.3M | 51.8M | |
Total Stockholder Equity | 27.7M | 27.2M | 11.3M | 27.2M | 70.8M | 74.3M | |
Net Debt | 16.2M | 19.4M | 35.8M | 7.9M | 116.4M | 122.2M | |
Retained Earnings | (74.0M) | (77.4M) | (95.4M) | (109.5M) | (133.9M) | (127.2M) | |
Cash | 4.7M | 4.1M | 42.2M | 96.3M | 74.1M | 77.8M | |
Cash And Short Term Investments | 29.9M | 32.6M | 50.7M | 96.3M | 82.8M | 86.9M | |
Common Stock Shares Outstanding | 26.5M | 25.9M | 26.8M | 27.5M | 32.6M | 34.2M | |
Liabilities And Stockholders Equity | 59.1M | 57.5M | 98.3M | 157.0M | 312.2M | 327.8M | |
Other Stockholder Equity | 101.7M | 104.6M | 106.7M | 136.7M | 204.6M | 214.9M | |
Total Liab | 31.7M | 30.6M | 87.4M | 130.1M | 241.8M | 253.8M | |
Total Current Assets | 36.8M | 40.1M | 60.7M | 118.3M | 139.5M | 146.5M | |
Accounts Payable | 7.4M | 3.6M | 5.2M | 18.6M | 21.4M | 22.5M | |
Non Current Liabilities Total | 19.4M | 19.8M | 77.7M | 111.5M | 192.4M | 202.0M | |
Other Current Assets | 786K | 941K | 1.3M | 22.0M | 9.4M | 9.8M | |
Property Plant And Equipment Net | 11.9M | 11.3M | 9.1M | 11.0M | 10.3M | 5.6M | |
Non Current Assets Total | 22.3M | 17.3M | 37.7M | 37.2M | 172.7M | 181.3M | |
Non Currrent Assets Other | 7.7M | 3.8M | 12.4M | 4.1K | (2.1M) | (2.0M) | |
Short Long Term Debt Total | 21.0M | 23.5M | 78.0M | 104.9M | 190.5M | 200.0M | |
Current Deferred Revenue | 57K | 66K | 16K | 113K | 75K | 71.3K | |
Short Term Debt | 2.4M | 5.1M | 560K | 723K | 806K | 765.7K | |
Accumulated Other Comprehensive Income | (2.8M) | (4.4M) | 0.0 | (409K) | (368.1K) | (386.5K) | |
Net Receivables | 2.7M | 2.7M | 4.5M | 6.4M | 36.5M | 38.3M | |
Short Term Investments | 25.2M | 28.5M | 8.5M | 5.6M | 8.7M | 10.8M | |
Inventory | 3.3M | 4.0M | 4.2M | 6.5M | 10.9M | 11.4M | |
Intangible Assets | 2.3M | 1.9M | 17.1M | 25.8M | 162.0M | 170.1M | |
Long Term Debt | 12.2M | 12.4M | 71.7M | 104.2M | 119.8M | 125.8M | |
Capital Surpluse | 101.7M | 104.6M | 106.7M | 137.1M | 157.6M | 113.7M | |
Property Plant Equipment | 11.9M | 11.3M | 3.1M | 3.5M | 3.1M | 5.7M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Equity 0.4484 |
The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.